Neurogene Reports Positive Long-term Data for NGN-401 Gene Therapy

Neurogene announced 30-month data showing participants significantly gained developmental milestones without plateauing or loss, demonstrating a durable therapeutic effect. This positive clinical progress for a rare disease treatment could boost investor sentiment as the company advances toward registrational trials.